Gilead's idelalisib hat trick

Share this article:

Gilead's Zydelig, formerly known as idelalisib, has been approved. The FDA greenlighted the drug for three cancers: chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Zydelig is a first-in-class phosphoinositide 3-kinase delta inhibitor. The drug snared breakthrough status for the CLL indication. Despite the first-in-class status, the drug already has competition, including CLL drugs Imbruvica (Johnson & Johnson) and Roche's Gazyva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.